Rein Therapeutics Inc (RNTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has a cash flow conversion efficiency ratio of -0.295x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($11.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Rein Therapeutics Inc (RNTX) total market value for the company's overall valuation and market capitalisation.
Rein Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Rein Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rein Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rein Therapeutics Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Rein Therapeutics Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DKME Co., Ltd.
KO:015590
|
-0.053x |
|
Medipower -M
TA:MDPR
|
0.025x |
|
PowerBank Corporation
NASDAQ:SUUN
|
-0.563x |
|
Enex Co.Ltd
KO:011090
|
-0.124x |
|
Litemax Electronics
TWO:4995
|
0.034x |
|
Inseego Corp
NASDAQ:INSG
|
0.778x |
|
Thorney Opportunities Ltd
AU:TOP
|
0.039x |
|
Kanpur Plastipack Limited
NSE:KANPRPLA
|
0.057x |
Annual Cash Flow Conversion Efficiency for Rein Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Rein Therapeutics Inc from 2015 to 2025. View RNTX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.92 Million | $-19.36 Million | -1.144x | -179.24% |
| 2024-12-31 | $54.39 Million | $-22.29 Million | -0.410x | +85.75% |
| 2023-12-31 | $6.89 Million | $-19.81 Million | -2.876x | -115.41% |
| 2022-12-31 | $18.62 Million | $-24.86 Million | -1.335x | -146.78% |
| 2021-12-31 | $43.90 Million | $-23.75 Million | -0.541x | +67.86% |
| 2020-12-31 | $12.16 Million | $-20.48 Million | -1.684x | -2.06% |
| 2019-12-31 | $16.05 Million | $-26.47 Million | -1.650x | -15.78% |
| 2018-12-31 | $19.60 Million | $-27.93 Million | -1.425x | -231.70% |
| 2017-12-31 | $47.80 Million | $-20.53 Million | -0.430x | -419.87% |
| 2016-12-31 | $-111.81 Million | $-15.01 Million | 0.134x | +8.16% |
| 2015-12-31 | $-94.32 Million | $-11.71 Million | 0.124x | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more